Key points:
- NATALEE Trial: Clinical implications of addition of ribociclib to endocrine therapy in adjuvant settings.
- Keynote 522 Update: Updated results demonstrating an overall survival benefit with the perioperative use of pembrolizumab.
- DESTINY Breast-12: Learn about the promising intracranial activity of trastuzumab durextecan in HER2-positive breast cancer patients with brain metastases.
In this episode of the Oncology Brothers podcast, we had the pleasure of discussing the latest advancements in breast cancer treatment presented at ESMO 2024 with Dr. Paolo Tarantino from the Dana-Farber Cancer Institute. We focused on three key studies that have the potential to significantly impact our clinical practice.
First, we delved into the NATALEE trial, which evaluated the use of ribociclib in the adjuvant setting for patients with early-stage ER-positive, HER2-negative breast cancer. The trial demonstrated that adding ribociclib to endocrine therapy improved invasive disease-free survival, even in node-negative patients. Notably, ribociclib received FDA approval shortly after the data was presented, marking a significant step forward in treatment options, albeit with the consideration of potential side effects over a three-year treatment period.
Next, we discussed the Keynote 522 trial, which highlighted the benefits of perioperative pembrolizumab combined with neoadjuvant chemotherapy in early-stage triple-negative breast cancer. The updated results showed a notable overall survival benefit, reinforcing the regimen as the current standard of care for this patient population.
Lastly, we explored the findings from the DESTINY Breast-12 study, which showcased the intracranial activity of trastuzumab durextecan in HER2-positive breast cancer patients with brain metastases. The results were promising, indicating that over half of the patients with brain metastases were free from recurrence after one year of treatment, further solidifying the role of TDXd in managing this challenging aspect of breast cancer.
Overall, this episode provided valuable insights into how these studies are refining our approach to breast cancer treatment, offering new hope and options for our patients. Thank you for tuning in, and be sure to check out our other episodes covering highlights from various oncology conferences!
